KNSA (Kiniksa Pharmaceuticals International) Institutional Ownership: 63.08% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KNSA Kiniksa Pharmaceuticals International PLC KNSA
50 GF Score
Price $64.63
GF Value $48.79
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Institutional Ownership?

Kiniksa Pharmaceuticals International KNSA +1.09% 50 Institutional Ownership is 63.08% as of Jul. 20, 2026. GuruFocus rates KNSA with a GF Score™ of 50/100 and a GF Value™ of $48.79 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kiniksa Pharmaceuticals International's institutional ownership is 63.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kiniksa Pharmaceuticals International's Insider Ownership is 0.98%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kiniksa Pharmaceuticals International's Float Percentage Of Total Shares Outstanding is 49.39%.

Kiniksa Pharmaceuticals International Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Institutional Ownership Chart

Kiniksa Pharmaceuticals International Historical Data

The historical data trend for Kiniksa Pharmaceuticals International can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 16.25 17.60 17.44 18.09 20.52 22.39 24.93 24.25 24.34 28.41
KNSA
50GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 63.08% mean?
Kiniksa Pharmaceuticals International (KNSA) has a Institutional Ownership of 63.08% as of Jul. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Institutional Ownership too high?
Kiniksa Pharmaceuticals International's current Institutional Ownership is 63.08%. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Institutional Ownership compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Institutional Ownership of 63.08% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Institutional Ownership is 63.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.79, compared to a current price of $64.63 — trading 32.5% above its estimated fair value. The current Institutional Ownership is 63.08%. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Institutional Ownership is 63.08% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.63 is trading 32.5% above its estimated GF Value™ of $48.79. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Institutional Ownership: 63.08%
  • GF Value™: $48.79 vs. price of $64.63 (32.5% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for KNSA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.63
Price
$48.79
GF Value